×
About 37,660 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  17,545 results

PAQR3 inhibits proliferation and aggravates ferroptosis in acute lymphoblastic leukemia...
https://doi.org/10.1002/iid3.437
Immunity, Inflammation and Disease; Jin L, Tong L

May 6th, 2021 - Acute lymphoblastic leukemia (ALL) is a usual hematological tumor, which was featured by malignant proliferation of lymphoid progenitor cells. Many important factors participate into the regulation of ALL, including proteins. PAQR3 (also named RKT...

RAG enhances BCR-ABL1 positive leukemic cell growth through its endonuclease activity i...
https://doi.org/10.1111/cas.14939
Cancer Science; Yuan M, Wang Y et. al.

May 5th, 2021 - BCR-ABL1 gene fusion associated with additional DNA lesions involves to the pathogenesis of chronic myelogenous leukemia (CML) from a chronic phase (CP) to a blast crisis of B lymphoid (CML-LBC) lineage and BCR-ABL1+ acute lymphoblastic leukemia (...

Racial and Economic Differences in the Risk of Hyperglycemia in Children Hospitalized W...
https://doi.org/10.1177/10434542211011040
Journal of Pediatric Oncology Nursing : Official Journal ... Savage B, Cole PD et. al.

May 5th, 2021 - Background: The underlying mechanism of hyperglycemia in children with acute lymphoblastic leukemia (ALL) is insulin resistance. Although race and economic status have been linked to increased insulin resistance in children, these have not been ex...

Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals t...
https://doi.org/10.1038/s41467-021-22787-9 10.1126/science.284.5415.770 10.1038/onc.2008.229 10.1016/j.cell.2009.03.045 10.1146/annurev-pathol-052016-100127 10.1038/ng.3909 10.1038/nrc.2016.63 10.1182/blood-2014-10-551895 10.1038/bcj.2015.80 10.1038/nrd4252 10.1016/j.ccell.2018.03.025 10.1084/jem.20070876 10.1016/j.cell.2013.05.041 10.1182/blood-2016-01-692855 10.1038/ng.2913 10.1073/pnas.1407079111 10.1038/nm1636 10.3324/haematol.2016.146381 10.1038/leu.2013.183 10.3324/haematol.2019.217687 10.1021/acs.jproteome.7b00602 10.1074/mcp.TIR119.001906 10.1016/j.cell.2006.09.026 10.1073/pnas.091062498 10.1093/bioinformatics/btq466 10.1093/nar/gkw377 10.1126/science.1259037 10.1093/nar/gky1131 10.1186/1471-2105-12-436 10.1021/acs.jproteome.8b00702 10.1016/j.cell.2017.10.049 10.1016/j.cell.2016.06.017 10.1038/nature11003 10.1158/1078-0432.CCR-18-0867 10.1182/blood-2006-08-039883 10.1073/pnas.1611831114 10.1182/blood-2008-02-136762 10.1016/S0891-5849(00)00317-8 10.1038/nrc2819 10.1182/blood-2008-03-147967 10.1158/0008-5472.CAN-08-4295 10.1126/science.aav4474 10.1038/s41587-019-0344-3 10.1371/journal.pone.0185762 10.1101/gad.211912.112 10.1073/pnas.1110570108 10.1126/scisignal.2003573 10.1038/nature13495 10.1016/j.ccell.2018.11.007 10.1016/j.cell.2005.10.024 10.1126/scisignal.2000475 10.1038/nm.4040 10.1038/s41389-017-0025-3 10.1016/j.biopha.2013.04.005 10.1016/j.cels.2017.07.005 10.1016/j.ccell.2016.03.012 10.1038/nm.3955 10.1038/s41467-018-03309-6 10.1016/j.cels.2017.05.009 10.1038/nbt.1511 10.1074/mcp.M114.044305 10.1038/s41467-020-14609-1 10.1038/nmeth.3901 10.1371/journal.pone.0224137 10.1093/nar/gky1106
Nature Communications; Franciosa G, Smits JGA et. al.

May 5th, 2021 - Notch1 is a crucial oncogenic driver in T-cell acute lymphoblastic leukemia (T-ALL), making it an attractive therapeutic target. However, the success of targeted therapy using γ-secretase inhibitors (GSIs), small molecules blocking Notch cleavage ...

see more →

Guidelines  45 results

Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 13th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

Children with Down syndrome, ALL at higher risk for poor outcomes
https://www.healio.com/hematology-oncology/leukemia/news/online/{4b3c1cc4-4e4a-462e-b738-7ee6b1d20fd3}/children-with-down-syndrome-all-at-higher-risk-for-poor-outcomes

May 30th, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.

Strict Cytogenetics, MRD Criteria Identifies Pediatric B-ALL Subgroup With Favorable Prognosis
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200195/full/

May 28th, 2020 - Application of a set of stringent clinical and cytogenetic features as well as minimal residual disease (MRD) criteria can identify a subset of low-risk (LR) pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who can...

Tisagenlecleucel Outcomes in Trial of Pediatric, Young Adult R/R ALL Are Consistent With Those Previously Reported
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200130/full/

May 12th, 2020 - In pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) who received prior blinatumomab exposure or inotuzumab ozogamicin as bridging therapy, treatment with tisagenlecleucel is associated with consistent ...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 7th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

see more →

Drugs  215 results see all →

Clinicaltrials.gov  18,663 results

PAQR3 inhibits proliferation and aggravates ferroptosis in acute lymphoblastic leukemia...
https://doi.org/10.1002/iid3.437
Immunity, Inflammation and Disease; Jin L, Tong L

May 6th, 2021 - Acute lymphoblastic leukemia (ALL) is a usual hematological tumor, which was featured by malignant proliferation of lymphoid progenitor cells. Many important factors participate into the regulation of ALL, including proteins. PAQR3 (also named RKT...

RAG enhances BCR-ABL1 positive leukemic cell growth through its endonuclease activity i...
https://doi.org/10.1111/cas.14939
Cancer Science; Yuan M, Wang Y et. al.

May 5th, 2021 - BCR-ABL1 gene fusion associated with additional DNA lesions involves to the pathogenesis of chronic myelogenous leukemia (CML) from a chronic phase (CP) to a blast crisis of B lymphoid (CML-LBC) lineage and BCR-ABL1+ acute lymphoblastic leukemia (...

Racial and Economic Differences in the Risk of Hyperglycemia in Children Hospitalized W...
https://doi.org/10.1177/10434542211011040
Journal of Pediatric Oncology Nursing : Official Journal ... Savage B, Cole PD et. al.

May 5th, 2021 - Background: The underlying mechanism of hyperglycemia in children with acute lymphoblastic leukemia (ALL) is insulin resistance. Although race and economic status have been linked to increased insulin resistance in children, these have not been ex...

Methotrexate - methotrexate tablet-Accord Healthcare Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=874c7f43-a3be-4236-89cc-24c44e3c5813

May 5th, 2021 - Methotrexate tablets is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1) Treatment of adults ...

see more →

News  1,189 results

Allo-HSCT Plus MAb Can Boost Survival in Patients With r/r B-ALL
https://www.medscape.com/viewarticle/948153

Mar 24th, 2021 - The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in minimal residual disease (MRD)-negative remission patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) after the start...

Clear Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
https://www.medscape.com/viewarticle/946711

Mar 2nd, 2021 - NEW YORK (Reuters Health) - Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favo...

TBI Beats Chemoconditioning for ALL Transplants in Children
https://www.medscape.com/viewarticle/945225

Feb 2nd, 2021 - For now at least, total body irradiation (TBI) plus etoposide remains the conditioning regimen of choice for children undergoing allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia (ALL), according to an open-label phase...

Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 13th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

'Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL
https://www.staging.medscape.com/viewarticle/939520

Oct 20th, 2020 - The days of using chemotherapy to treat Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) may be numbered. In a phase 2 trial, up-front chemo-free induction/consolidation with the tyrosine kinase inhibitor dasatinib (Sprycel)...

see more →

Patient Education  3 results see all →